Purpose of review It has been demonstrated that extensive virus diversification and antibody coevolution are necessary to give rise to broadly neutralizing antibodies targeting the envelope protein of HIV-1. Here, we discuss recent progress of vaccine design approaches aiming on strategies to initiate and guide B-cell development toward this outcome, as well as their evaluation in mouse models engineered to express human antibodies.
INTRODUCTION
Several studies in nonhuman primates clearly demonstrated that passive immunization using broadly neutralizing monoclonal antibodies can provide sterilizing protection against viral challenges [1, 2] . Furthermore, a first-in-man dose escalation phase 1 clinical trial of 3BNC117, a potent human CD4 binding site antibody, reduced the viral load in HIV-1-infected individuals by 0.8-2.5 log 10 , and viremia remained significantly reduced for 28 days [3] . Hence, the induction of broadly neutralizing antibodies (bnAbs) at sufficiently high titers could presumably protect humans against HIV infection [4 & ,5] . Therefore, it is generally agreed that the capability to elicit a broad cross-neutralizing antibody (bnAb) response is a desirable feature of an effective HIV vaccine.
Despite encouraging results of RV144 in mediating transient and partial protection from acquisition of HIV (vaccine efficacy of 31%) [6] , it became quickly clear that these effects could not be attributed to neutralizing antibodies. Neither vaccination regimens using recombinant and adjuvanted envelope (Env) proteins as the sole vaccine component, nor regimens combining vectored Env delivery with an adjuvanted Env protein administration were capable of eliciting bnAbs [7] [8] [9] . This has been attributed to the immunodominance of highly variable surface regions in the gp120 monomer or the nonstabilized, open conformation gp140 Env trimer; extensive glycan shielding, conformational masking and steric occlusion of neutralizationsensitive epitopes (see contribution of Ramirez et al., in this issue); a generally low affinity of germline receptors of bnAb producing B-cell-progenitors to the available immunogens and ultimately the fact, that selection mechanisms in the germinal centers of the secondary lymphatic organs are not sampling for functional (neutralizing) antibodies but instead for B cells presenting immunoglobulin receptors with high affinity [10, 11] . Lessons learned from prospective virus and B-cell coevolution studies [12] [13] [14] [15] [16] [17] [18] on the rare HIV-1-infected individuals who developed bnAbs [19, 20] led to the hypothesis that different versions of the antigen may be necessary to shepherd the B-cell development from germline precursors to mature bnAbproducing species [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] 22 & ,25 & ]. If those should be administered in a cocktail format (as mixture) by sequential immunization or with a combined strategy is currently being investigated by several groups [32, 33] .
First-generation and second-generation broadly neutralizing antibodies
The magic bullet of successful vaccination against HIV would be an antigen eliciting broad antibodymediated sterilizing immunity against the majority of circulating HIV-1 strains. However, all vaccination trials performed in humans and using Env proteins have so far failed to induce antibody responses with the desired neutralization potency and breadth [34] . Therefore, part of HIV vaccine research during the past decade progressively focused on studying plasma-derived and lymph node-derived B cells [35] as well as their development in HIV-infected individuals [36] , currently resulting in what has been termed 'reverse vaccinology 2.0' [37] . Data generated during that period until today not only revealed various neutralization-sensitive sites on the viral Env [4 & ] but also led to current considerations regarding Env immunogen design [38 & ] (see contribution by Ramirez et al., in this issue), vaccine formulation and delivery as well as vaccination regimens [39] .
Isolation and characterization of bnAbs have been pioneered already in the late 1990s by Katinger et al., respectively, with the identification of specific neutralizing antibodies such as 2F5 and 4E10 (gp41 MPER), 2G12 (gp120 outer domain, glycandependent), b12 (CD4 binding-site) and 447-52D (V3 crown), thus shedding light on the first identified vulnerable sites of Env (thoroughly reviewed by Burton and Hangartner [4 & ]) . Identification of a larger number of 'second-generation' bnAbs from a limited number of selected HIV-infected individuals (CATNAP database [40] ) was enabled by the development of converging platform technologies. These platforms allowed for efficient high-throughput culturing, activation and immortalization of B cells followed by screening of supernatants from individual memory B cells for neutralization or, alternatively, B-cell sorting, molecular recloning of genes encoding antibody fragments and functional screening of the expressed antibodies [4 & ]. A broad range of bnAb epitopes was identified, mapped and characterized thoroughly, which shaped our view of the vulnerability of the viral Env and, at the same time, revealed mechanisms that enable the virus to reduce the opportunities for the bnAb development [41] . The extended availability of sequence data furthermore revealed that the level of somatic hypermutation (SHM) as well as the length of heavy-chain complementarity determining region 3 in bnAbs is generally extremely high making them to real 'freaks of nature' [42] .
Germline targeting
Insights into the complex coevolution process of the virus and virus-neutralizing antibodies [14] [15] [16] [17] , the finding that Env trimers have low affinities to the inferred germline B-cell receptors of bnAbproducing precursor B cells [43] [44] [45] and, conversely, higher affinities to non-neutralizing germline B-cell receptors [46, 47] support the hypothesis that priming of the key germline B cells by germline-targeting immunogens would be a necessary first step in the process eventually leading to bnAbs [44, 48] . A number of studies have recently presented immunogens designed to specifically target the germline receptors of bnAb B cells [24,25 & , 49,50 & ]. bnAbs inferred germline precursors are generally not broadly crossreactive [15] , and high levels of SHM in bnAbs imply the selection of the B cells that produce them in multiple rounds of affinity maturation. Hence, a number of guide immunogens representing milestone variants of Env during viral escape have to be identified, pushing the development of B cells to the desired destination. Several recent publications have described such immunogen collections and methods for their design and selection.
Immunogens to guide B-cell responses
The design of Env-based immunogens started early with Env-peptides and gp120 molecules [51] and went a long way until a major breakthrough with
KEY POINTS
Extensive virus/antibody coevolution is necessary to elicit bnAbs.
Sequential immunization with a panel of carefully designed envelope immunogens may be required to elicit bnAbs.
Several transgenic mouse models displaying prerearranged germline and mature heavy-chain and light-chain genes are available to study the concept of sequential immunization.
Sets of sequential immunogens are capable of eliciting antibody responses that neutralize a broad panel of native or near-native tier 2 viruses.
the introduction of the stabilized SOSIP by Sanders and Moore (reviewed by Sliepen and Sanders [38 & ]). Particularly, the BG505 SOSIP.664 gp140 (from a subtype A virus isolated from a 6-week-old, HIV-1-infected infant) gave insights into Env structure, structural states, rearrangements and glycosylation [52] [53] [54] [55] [56] [57] 54 & ]. Based on these findings, it was hypothesized that native-like, closed conformation Env trimers are to be preferred over substructures like gp120-variants because Env immunogens need to present sites of vulnerability and at the same time hide non-neutralizing epitopes [46, 58] ; quaternary epitopes (targeted by e.g. PGT145, PG9, PGT151, 35O22) are ideally properly presented and because the trimers allow for cross-linking of multiple B-cell receptors, which facilitates the germinal center reaction. Yet, despite these improvements, immunization studies with stable and hyperstable [59] [60] [61] [62] Env trimers have to date merely shown the elicitation of autologous tier 2 neutralization responses [63, 64] . Therefore, the efforts on designing optimized Env-based vaccines are currently focusing on targeting the immune reaction on vulnerable sites [e.g. by scaffolding or by glycan shielding (see contribution of Ramirez et al. in this issue)] and on modifying Env to enable binding of germline versions or intermediates in the developmental pathway to bnAbs.
To this end, rational protein design [27] or computational design methods combined with directed evolution approaches like high-throughput yeast cell surface display [24] or mammalian cell display [65 && ,66] led to a new generation of sequential immunogens with narrowly defined binding properties and the capacity to guide B-cell development. In all cases, affinity to mature bnAbs and their inferred germline variants as well as partially reverted intermediates guided the design and helped for the selection of proteins. In parallel, avidity of the immunogens in particular with regard to the engagement of germline B-cell receptors with low affinity was optimized via different particlebased presentation formats (see contribution by Asbach et al. in this issue).
Immunization studies in transgenic mice
To analyze the capacity of the developed (serial) immunogens to engage and expand the respective germline B-cell receptors in vivo, different genetically engineered transgenic mouse models have been established, which try to compensate for the lack of orthologs of naïve human B cells capable of developing into bnAb-producing B cells (Table 1) .
All recent transgenic mouse models were generated by stem cell gene targeting [71] . Depending on the complexity of the model, prerearranged or nonrearranged germline or mature VDJH and VJL loci have been introduced. The knocked-in human antibody transgenes are active due to allelic exclusion [72] , and the B cells express primarily the knockedin human B cell receptor ( Fig. 1 and Table 1 ). As lambda and kappa light-chain genes and heavychain genes are not genetically linked and hence segregate independently, prerearranged VDJH and VJL genes can be studied independently from each other. Thus, prerearranged light-chain or heavychain genes can be expressed separately with the endogenous mouse repertoire or alternatively can be combined by crossbreeding, leading to a mouse primarily expressing the complete transgenic B-cell receptor. Latest developments yielded mice (referred to as Kymab mice) carrying the complete naïve human immunoglobulin heavy-chain and lightchain repertoire (mouse constant regions intact), thereby approaching a more comparable situation with the human setting [73] . , proved to induce B-cell responses in these mice which were, however, not neutralizing. Similar to the results from the CD4bs-directed bnAb models, native-like trimers failed to engage the germline Bcell receptor and did not induce B-cell responses in these mice.
To investigate the possibility of targeting specific precursor B cells with certain germline receptors in a human-like B-cell repertoire setting, the abovementioned eOD-GT8 was used to immunize Kymab mice [73] After immunization, 29% of the mice responded to the immunization and 1% of CD4-binding-sitespecific B cells were indeed VRC01 precursors (1.6 cells per mouse).
Sequential immunization studies
Taking into account that the development of bnAbs usually requires extensive antigen exposure over a long period of time [74, 75] , that clonal bnAb producing B-cell development in HIV-infected individuals coevolves with the diversification of the virus [12] [13] [14] [15] [16] [17] [18] and that germline B-cell receptors are unable to bind native Env, it is fair to hypothesize that a germline-targeting priming immunization requires booster immunizations with one or more Env variants to shape the B-cell maturation toward mature bnAbs. This approach -to shepherd the immune response toward bnAbs -has been adopted as 'sequential immunization' strategy [48, 76, 26] . A proof of this concept came from the above described study that investigated knock-in mice carrying the mature heavy-chain 3BNC60 gene together with the naïve mouse light-chain repertoire representing an intermediate stage in the developmental route from the naïve B-cell receptor to the bnAb-expressing B cells [22 & ]. Immunization of the mice with germlinetargeting antigens (eOD-GT8 60-mer or multimerized 426c TM4DV1-3) generated antibodies that only neutralized HIV-1 strains with incomplete glycosylation (position 276), whereas immunization with native-like trimers (BG505 SOSIP or YU2 SOSIP) elicited heterologous tier 2 neutralizing antibodies (with short five amino acid CDR3 loops, avoiding steric hindrance with glycan 276).
Consequently, if germline targeting immunogens can activate naïve bnAb precursors and if, on the other hand, intermediates (like the mature heavy-chain 3BNC60 paired with short mouse CDR3 loops) can be selected by native trimers, the goal would be to induce the intermediates by a certain number of intermediate-stimulating immunogens. Three recent studies followed this strategy, either targeting the CD4 binding site [ ] used germline VRC01 mice generated earlier by Jardine et al. [25 & ] for their study. The mice express the germline heavy-chain V (VH1-2 Ã 02) and J (IGHJ1 Ã 01) gene in conjunction with the mature VRC01 CDR3 loop as surrogate for the unknown germline D gene, V-D and D-J junctions, paired with the naïve mouse light-chain repertoire. The mice were primed by immunization with germline-targeting multimerized eOD-GT8, boosted with BG505-GT3 (a gp120 core that has been selected by yeast-display methods exhibiting low affinity to germline and high affinity to mature VRC01) followed by two further boosts with native trimer (based on BG505 SOSIP). The trimers used for the final boosts were lacking the N276 glycan that generally inhibits germline VRC01 binding but is present in 95% of all viruses. In consequence, the resulting sera had some breadth but were unable to neutralize virus strains comprising the N276 glycan. The authors state that the elicited antibodies may be partially mature VRC01-class antibodies. Hence, one or more additional antigens are needed to guide maturation of CD4bs-directed antibodies toward sufficient affinity for fully glycosylated Env.
A more sophisticated mouse model was used by Tian et al. [67 && ]. Here, the human VH1-2 Ã 02 sequence was recombined into the mouse germline locus, replacing the most D-proximal V-segment (Fig. 1c) . Furthermore, the intergenic control region 1 was deleted, favoring recombination using the VH1-2 Ã 02 segment (along with deletion of the J region from the IgH allele in trans). The authors showed by high-throughput antibody repertoire sequencing that a larger proportion (approximately 40%) of the B cells expressed IGHV1-2 Ã 02, when in parallel a predicted precursor of the VRC01 lightchain was knocked in. The mice were immunized with germline-targeting eOD-GT6 60mer followed by a series of Env gp120s and SOSIP trimers (based on 426c) with increasing number of CD4-bindingsite-surrounding glycans. This protocol simulates an incrementally growing glycan fence [77] that generally hampers the binding of antibodies to the CD4 binding site. Sera from these mice showed broad neutralization of a panel of viruses in which the N276 glycan was deleted (N276A). It remains to be shown if and how the final adaption of VRC01 precursors may be accomplished. Probably, further maturation-guiding immunogens will prove valuable here.
In an analogous study [69 && ], mice expressing the inferred germline heavy-chain and light-chain of PGT121 were immunized with a series of affinitymaturation-guiding antigens [65 && ]. In this case, homozygote mice solely expressing germline heavy-chain and light-chain receptors (confirmed by single B-cell sequencing) were generated. As initial germline-targeting antigen, a trimeric BG505-SOSIP derivate with deleted glycans at positions N137 and N133 (10MUT SOSIP), previously shown to bind germline PGT121, was administered. Prior to a final boost with native-like BG505-SOSIP.664 trimer (a mixture of variants differing in the variable loops), a number of boosting variants were administered, which were designed rationally and then selected from targeted randomization libraries using an elegant mammalian display system and FACS sorting procedure [65 && ]. These variants were initially qualified in vitro by measuring K D values against germline-reverted and intermediate PGT121 variants that contained an increasing number of mature PGT121 mutations. For the following in-vivo experiments, assorted immunogens were chosen which showed increasing affinities for the mature and decreasing affinity for the germline version of PGT121. The applied immunization regimen yielded PGT121-like antibodies in the mice that featured high levels of somatic mutations and resembled key mutations of the human bnAb, thus showing significant potency and breadth against heterologous tier 2 isolates.
In summary, antibody-guided, epitope-focused vaccine designs [78 & ] combined with sequential immunizations demonstrated for the first time the feasibility of eliciting bnAbs in vivo. Noteworthy, some of these advances were made in mouse models in which no polyclonal response with competition between the desired naïve B cells and high affinity B cells against off-target epitopes are present.
CONCLUSION
Eliciting HIV-1 bnAbs in humans by a vaccine would certainly mark a turning point in the fight against AIDS. The complex nature of such antibodies, however, emphasizes the need for more elaborate vaccination strategies than those that had been pursued in the past. Recent work has shown unprecedented progress toward the identification of optimal immunogen designs and successful sequential immunization schemes in a variety of humanized mouse models displaying increasingly complex B-cell responses. Two vulnerable sites, the CD4 binding site and the high mannose patch, have been investigated in detail as potent epitopes selected for targeted B-cell stimulation. Further efforts will be undertaken to engage germline B-cell receptors and to stimulate B-cell lineage development toward bnAbs targeting other vulnerable epitopes. Despite these very elegant experiments and the increasingly encouraging results, it has to be emphasized that these advances were made in low-bar in-vivo models. It is therefore largely unclear to which extent B-cell responses can be guided in an outbred situation, to what extent host genetics will influence the outcome of sequential immunizations, whether sufficiently high titers of bnAbs will be reached and how long-lasting those responses will be. Although arguing against the abovereported recent findings, simplified immunization regimens would be highly desirable in particular in view of the primary target population for a prophylactic vaccination in poor countries. Whether or not advanced adjuvants, clever depot/release formulations, optimized immunogen cocktails or prime/boost regimens may add to overcome some of these obstacles remains to be elucidated.
